공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

B형 간염 : 파이프라인 리뷰

Hepatitis B (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 232823
페이지 정보 영문 654 Pages
가격
US $ 2,500 ₩ 2,959,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,919,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,878,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


B형 간염 : 파이프라인 리뷰 Hepatitis B (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 654 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

B형 간염은 생명을 위협할 위험성이 있는 간의 감염증입니다. B형 간염 바이러스는 황달, 암색뇨, 중증의 권태감, 오심, 구토, 복통을 수반하는 급성 질환의 원인이 될 수 있습니다. B형 간염으로 이환하는 위험인자로 노령화, 중증의 신장병, 혈우병, 주사바늘 재사용, B형 간염에 감염된 산모로부터의 출생 등을 들 수 있습니다. 항바이러스제 등으로 치료합니다.

B형 간염(Hepatitis B) 치료제 개발 상황에 대해 조사했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향 등의 정보를 전해드립니다.

서론

B형 간염 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Hepatitis B, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Hepatitis B - Pipeline by Abhelix LLC, 2021
  • Hepatitis B - Pipeline by Ai-biopharma SAS, 2021
  • Hepatitis B - Pipeline by AiCuris AG, 2021
  • Hepatitis B - Pipeline by Akshaya Bio Inc, 2021
  • Hepatitis B - Pipeline by Aligos Therapeutics Inc, 2021
  • Hepatitis B - Pipeline by AlloVir Inc, 2021
  • Hepatitis B - Pipeline by AlphaMab Co Ltd, 2021
  • Hepatitis B - Pipeline by Alphamab Oncology, 2021
  • Hepatitis B - Pipeline by Altimmune Inc, 2021
  • Hepatitis B - Pipeline by Antios Therapeutics Inc, 2021
  • Hepatitis B - Pipeline by Apros Therapeutics Inc, 2021
  • Hepatitis B - Pipeline by Arbutus Biopharma Corp, 2021
  • Hepatitis B - Pipeline by Arcturus Therapeutics Holdings Inc, 2021
  • Hepatitis B - Pipeline by Ascentage Pharma Group International, 2021
  • Hepatitis B - Pipeline by Ascletis Pharma Inc, 2021
  • Hepatitis B - Pipeline by Assembly Biosciences Inc, 2021
  • Hepatitis B - Pipeline by Atea Pharmaceuticals Inc, 2021
  • Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC, 2021
  • Hepatitis B - Pipeline by Auro Vaccines LLC, 2021
  • Hepatitis B - Pipeline by Avalia Immunotherapies Ltd, 2021
  • Hepatitis B - Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2021
  • Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, 2021
  • Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
  • Hepatitis B - Pipeline by Benitec Biopharma Inc, 2021
  • Hepatitis B - Pipeline by Biological E Ltd, 2021
  • Hepatitis B - Pipeline by Biomics Biopharma Ltd, 2021
  • Hepatitis B - Pipeline by BioNet-Asia Co Ltd, 2021
  • Hepatitis B - Pipeline by Biotron Ltd, 2021
  • Hepatitis B - Pipeline by Bolder Biotechnology Inc, 2021
  • Hepatitis B - Pipeline by Bonac Corp, 2021
  • Hepatitis B - Pipeline by Brandenburg Antiinfektiva GmbH, 2021
  • Hepatitis B - Pipeline by Brickell Biotech Inc, 2021
  • Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, 2021
  • Hepatitis B - Pipeline by Bukwang Pharmaceutical Co Ltd, 2021
  • Hepatitis B - Pipeline by Cadila Healthcare Ltd, 2021
  • Hepatitis B - Dormant Projects, 2021
  • Hepatitis B - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Hepatitis B, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2021, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 46, 36, 4, 102, 43 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 8 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Hepatitis B - Overview
  • Hepatitis B - Therapeutics Development
  • Hepatitis B - Therapeutics Assessment
  • Hepatitis B - Companies Involved in Therapeutics Development
  • Hepatitis B - Drug Profiles
  • Hepatitis B - Dormant Projects
  • Hepatitis B - Discontinued Products
  • Hepatitis B - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q